Kyocera buys part of Renovis Surgical

Kyoto, Japan-based Kyocera (TYO:6971) said it will buy the major assets of Renovis Surgical Technologies’ artificial joint and spinal products businesses to expand its U.S. footprint.

Kyocera will transfer the assets into a new, wholly owned, California-based company to be named Kyocera Medical Technologies in March 2019. Kyocera manufactures medical products, including artificial joints and dental implants, primarily for the Japanese market. The company obtained 510(k) clearance for its artificial hip joints in 2017 and began selling them in the U.S. the following year.

Founded in 2009, Renovis (Redlands, Calif.) designs and manufactures implants for the orthopedic and neurological markets and for trauma surgery. The company won 510(k) clearance for its Tesera X Lateral Interbody Fusion System in 2018. Tesera X uses the company’s 3D-printed porous architecture that is made using additively manufactured titanium alloy. Renovis has also developed an advanced bearing surface technology for joint replacement products.

The new company will use Kyocera’s proprietary technologies and those purchased from Renovis to develop new products, according to Kyocera, which also manufactures semiconductor packages, industrial and automotive components, electronic devices, solar power generating systems, printers, copiers and mobile phones. During the year ended March 31, 2018, Kyocera’s consolidated net sales totaled 1.58 trillion yen (approximately $14.9 billion).

Theranos whistleblower Tyler Shultz to participate in keynote interview at DeviceTalks Boston At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos. Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston. REGISTER NOW